Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Fallopian Tube Carcinoma: early-phase trial registry
6 of 14 indexed Fallopian Tube Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,230 of 28,707 conditions by registered trial count.
14 US clinical trials · 6 currently recruiting · #1,230 of 28,707 conditions by registered trial count
Fallopian Tube Carcinoma: 14 US clinical trials tracked, 6 recruiting.
Fallopian Tube Carcinoma is the subject of 14 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 3 of these trials.
Enrollment posture brief
Registry condition fallopian-tube-carcinoma
OPEN 6 | RECR 43% | LATE 0 | EARLY 10 | RANK #1230 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Acute Myelogenous Leukemia (AML) (43% recruiting · 7 trials)
Fallopian Tube Carcinoma lists 6 open slots (43% of 14 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Fallopian Tube Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Fallopian Tube Carcinoma is recruiting below its size-band peers.
6 of 14 indexed trials (42.9%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Fallopian Tube Carcinoma research.
National Cancer Institute (NCI) accounts for 3 of 14 trials (21.4%). 10 distinct sponsors appear on at least one study for this condition label.
-
Most Fallopian Tube Carcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 70 among the 14 trials that report a genuine target (sentinel values excluded). 9 of those (64.3%) plan for fewer than 100 participants.
-
Fallopian Tube Carcinoma research is mostly interventional.
12 interventional and 2 observational studies make up this index (85.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
14 total, page 1 of 1
National Cancer Institute "Cancer Moonshot Biobank"
National Cancer Institute (NCI)
NCT04314401
Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF
M.D. Anderson Cancer Center
NCT03604315
REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors
Dana-Farber Cancer Institute
NCT06710548
Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery
Memorial Sloan Kettering Cancer Center
NCT06290193
Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers
Emory University
NCT06492070
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
NCT07285044
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer
National Cancer Institute (NCI)
NCT01116648
Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer
National Cancer Institute (NCI)
NCT02345265
HOT: HIPEC in Ovarian Cancer as Initial Treatment
Mercy Medical Center
NCT02124421
Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy
Memorial Sloan Kettering Cancer Center
NCT04204811
Standardized Extract of Cultured Lentinula Edodes Mycelia (AHCC®) in Ovarian Cancer Patients on Adjuvant Chemotherapy
University of California, Davis
NCT05763199
Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer
Gynecologic Oncology Group
NCT01139957
A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Gynecologic Oncology Group
NCT00939809
Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Tracon Pharmaceuticals
NCT01381861
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 8 |
Top Sponsors
Named interventions
Most-linked intervention names on Fallopian Tube Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Fallopian Tube Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Fallopian Tube Carcinoma page
14 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 6 Fallopian Tube Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Fallopian Tube Carcinoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Fallopian Tube Carcinoma condition card totals 14 registered trials; most-linked intervention Computed Tomography; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.